BIBLIOGRAFIA
•
Wynder EL. The past, present, and future of the prevention of lung cancer. Cancer Epidermal.Biomarkers Prev.1998;7:735-748
•
Sekido Y, Fong KM, Minna JD: Molecular genetics of lung cancer. Annu Rev Med 54:73-87,2003
•
Jemal A et al. Cancer statics 2009. CA cancer J Clin 2009; 59:225-49
•
Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer GENE 366: 2-16, 2006
•
Eberhad DA, Johnson B.E, Amler LC e coll: Mutations in the epidermal growth factor receptor and in KRAS are predeictive and prognostic indicators in patients with non-small-cell lung cancer trated with chemioterapy alone and in combination with Erlotini. J Clin Oncol 23, 5900-5909, 2005
•
Ciardiello F, Tortora G: EGFR antagonistis in cancer treatment. N Engl J Med 358: 1160-74, 2008
•
Eberhad DA, Giaccone G, Johnson BE: Non small-Cell Lung Cancer Lung Cancer Working group. Biomarkers of response to epidermal growth factor receptor inhibitors in NSCLC Working group: Standardization for use in clinical trial setting. J Clin Oncol 26:983-94, 2008
•
Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in NSCLC. Analysis of a large serven of cases and development of a rapid and
84